Actual questions of medicine therapy of hormonoresistant and metastatic prostate cancer



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prostate cancer (PC) is a heterogeneous disease with several different stages necessitating a broad range of therapies to treat patients diagnosed at different points in the disease course. Androgen deprivation therapy (ADT) is commonly used to treat aii stages of prostate cancer but is associated with toxicities that limit its use, particularly in patients with asymptomatic disease or existing comorbidities for whom such toxicity is not justified. ADT resource at patients with PC is limited and makes about 18-24 months then illness progresses and accepts generalised and/or hormone-resistant form. In this connection the factor develops various regimens ADT such as - an intermittent hormone therapy (IHT) which is investigated as alternative continuous HT. Study of 2 phases have shown efficiency IHT, improvement of quality of a life. It is noted that IHT has no negative effect for the period of development of advance and/or on survival rate. Despite advantage of a docetaxel in treatment of patients of generalised form PC, survival rate medians makes about 2,4 months, and treatment carrying out is interfaced to high toxicity. Low efficiency of existing drugs - also is a vital issue limiting efficiency of treatment of patients with hormone-resistant and metastatic forms of PC.

Full Text

Restricted Access

References

  1. Бухаркин Б.В. Гормональное лечение местнораспространенного и диссеминированного РПЖ // Клиническая онкоурология / под. ред. проф. Б. П. Матвеева. М., 2003. С. 560-563.
  2. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2006 г. М., 2006. С. 7-10, 100-102.
  3. Huggins С., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate // Cancer Res. 1941. № 1. P. 293-297.
  4. Loblaw D.A., Virgo K.S., Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline // J. Clin. Oncol. 2007. №25. P. 1596-1605.
  5. Basch E.M., Somerfield M.R., Beer T.M. et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice guideline on nonhormonal. therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer // J. Clin. Oncol. 2007. №25. P. 5313-5318.
  6. Saigal C.S., Gore J.L., Krupski T.L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer // Cancer. 2007. № 110. P. 1493-1500.
  7. Bylow K., Mobile S.G., Stadler W.M. et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review // Cancer. 2007. № 110. P. 2604-2613.
  8. Higano C.S. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? // Nat. Clin. Pract. Urol. 2008. № 5. P. 24-34.
  9. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer // J. Natl. Cancer Inst. 2003. № 95. P. 981-989.
  10. Holmberg L., Bill-Axelson A., Helgesen F. et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer // N. Engl. J. Med. 2002. №47. P.781-789.
  11. Kirk D. Timing and choice of androgen ablation // Prostate Cancer Prostatic Dis. 2004. № 7. P. 217-222.
  12. Byar D.P Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate // Cancer. 1973. № 32. P. 1126- 1130.
  13. Schroder F.H., Kurth K.H., Fossa S.D. et al. Early versus delayed endocrine treatment of pNl-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study // J. Urol. 2004. № 72. P. 923-927.
  14. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lym-phadenectomy in men with node-positive prostate cancer // N. Engl. J. Med. 1999. № 341. P. 1781-1788.
  15. Maffezzini M., Bossi A., Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer// Eur. Urol. 2007. № 51. P. 605-613.
  16. Kim-Sing C., Pickles T. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database // Int. J. Radiat. Oncol. Biol. Phys. 2004. № 60. P. 463-469.
  17. Smith D.C., Redman B.G., Flaherty L.E. et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer // Urology 1998. №52. P.257-260.
  18. Wilkinson S., Chodak G. An evaluation of intermediate dose ketoconazole in hormone refractory prostate cancer// Eur. Urol. 2004. № 45. P. 581-584.
  19. Small E.J., Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer // Cancer. 1995. №76. P. 1428-1434.
  20. Kruit W.H., Stoter G., Klijn J.G. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy // Anticancer Drugs 2004. № 15. P. 843-847.
  21. Labrie F., Cusan L., Gomez J.L. et al. Long-term combined androgen blockade alone for localized prostate cancer// Mol. Urol. 1999. № 3. P. 217-226.
  22. Tannock I.F., de Wit R., Berry W.R. et al. Docetax- el plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer // N. Engl.1. Med. 2004. № 351. P. 1502-1512.
  23. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer//N. Engl. J. Med. 2004. № 351. P. 1513- 1520.
  24. Heng D.Y., Chi K.N. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer // Can. J. Urol. 2006. № 13. P. 3335-3339.
  25. Tu S.M., Lin S.H. Current trials using bone-targeting agents in prostate cancer // Cancer J. 2008. № 14. P. 35-39.
  26. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer // Eur. Urol. 2008. № 53. P. 68-80.
  27. Boccon-Gibod L. Optimising hormone therapy in advanced disease // Eur. Urol. Suppl. 2005. № 4 (8). P. 21-29.
  28. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight // BJU Int. 2007. № 99 (Suppl. 1). P. 19-22.
  29. Mottet N., Prayer-Galetti T., Hammerer P. et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer // BJU Int. 2006. № 98. P. 20-27.
  30. Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity // Urology. 2003. № 61 (Suppl. 1). P.32-38.
  31. Keating N.L., O’Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer// J. Clin. Oncol. 2006. № 24. P. 4448M456.
  32. D’Amico A.V., Denham J.W., Crook J. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions // J. Clin. Oncol. 2007. № 25. P. 2420-2425.
  33. Saigal C.S., Gore J.L., Krupski T.L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer// Cancer. 2007. № 110. P. 1493-1500.
  34. Boccon-Gibod L., Hammerer P., Madersbacher S. et al. The role of intermittent androgen deprivation in prostate cancer // BJU Int. 2007. № 100. P. 738-743.
  35. Robinson M.R., Smith P.H., Richards B., Newling D.W. et al. The final analysis of the EORTC Genitourinary Tract Cancer Co-operative Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate, and low dose stilboestrol in the management of metastatic carcinoma of the prostate // Eur. Urol. 1995. № 28. P. 273-283.
  36. Akakura K., Bruchovsky N., Goldenberg S.L. et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate- specific antigen // Cancer. 1993. № 71. P. 2782-2790.
  37. Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma // Cancer Res. 1990. № 50. P. 2275-2282.
  38. Rennie P.S., Bruchovsky N., Akakura K. et al. Effect of tumour progression on the androgenic regulation of the androgen receptor / TRPM-2 and YPT1 genes in the Shionogi carcinoma // J. Steroid. Biochem. Mol. Biol. 1994. №50. P.31-40.
  39. Bruchovsky N., Goldenberg S.L., Akakura K. et al. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethyl- stil-bestrol // Cancer. 1993. № 72. P. 1635-1691.
  40. Gleave M.E., Goldenberg S.L., Jones E.C. et al. Biochemical and pathological effects of 8 mo of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer//J. Urol. 1996. № 155. P. 213-219.
  41. Eggener S.E., Stem J.A., Jair. P.M. et al. Enhancement of intermittent androgen ablation by ,,off-cycle“ maintenance with finasteride in LNCaP prostate cancer xenograft model // Prostate. 2006. № 66. P. 495-502.
  42. Shaw G.L., Wilson P., Cuzick J. et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients // BJU Int. 2007. № 99. P. 1056- 1065.
  43. Hussain M., Tangen C.M., Higano C. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) // J. Clin. Oncol. 2006. № 24. P. 3984-3990.
  44. Miller K., Sterner U., Lingnau A. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer // J. Clin. Oncol. 2007. № 25. P. 2385, abstract 5015.
  45. Calais Da Silva FM, Calais Da Silva F. et al. Phase III intermittent МАВ vs continuous МАВ // J. Clin. Oncol. 2006. № 24. P. 220, abstract 4513.
  46. Salonen A.J., Viitanen J., Lundstedt S. et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation // J. Urol. 2008. № 180. P. 915-919.
  47. Tunn U., Kurelc R., Kienle E. et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy (RP) // J. Urol. 2004. № 171. P. 384, abstract 1458.
  48. Tunn U.W., Сапера G., Hillger H. et al. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy - final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Kaprin A.D., Gafanov R.A., Shaipov M.K., Shestakov A.V., Meskich A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies